Federico Cayol, Iván Macharashvili, Jessica Barochiner, María Pía Dominguez, Emiliano Menna, Pablo Jose Perez Mesa, Julieta Pandolfi, Omar Carranza, Rodrigo Sanchez, Andrea Marchioni, Geraldine Gueron, Luz Pena, Matias Cerini, Hernan Cutuli, Hernan Garcia Rivello, Gonzalo Taetti, Augusto Ferreyra Camacho
A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.
PURPOSE: The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited.
MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT).
RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification.
CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.